Kurse werden geladen...
Prognose
Das durchschnittliche Kursziel der Analysten beträgt 111,97€(−43,31%). Der Median liegt bei 111,97€(−43,31%).
Kaufen | 1 |
Halten | 0 |
Verkaufen | 1 |
Scoring-Modelle
Dividenden-Strategie | 9 / 15 |
HGI-Strategie | 3 / 18 |
Levermann-Strategie | -3 / 13 |
News
ALX Oncology to Host R&D Webcast Event Highlighting its Novel EGFR Targeting Antibody-Drug Conjugate, ALX2004, on May 20, 2025
SOUTH SAN FRANCISCO, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives, today announced that it will host a webcast event on May 20, 2025, to provide an update on ALX2004, the Company's potentially best- and first-in-class investigational antibody-drug conjugate (ADC). The webcast will highlight the novel mechanism of action, preclinical data and clinical development strategy for ALX2004 following clearance of the Investigational New Drug application from the U.S. Food and Drug Administration earlier this year.» Mehr auf globenewswire.com
All You Need to Know About Alexander's (ALX) Rating Upgrade to Strong Buy
Alexander's (ALX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.» Mehr auf zacks.com
ALX Oncology Reports First Quarter 2025 Financial Results and Provides Corporate Update
Following announcement of prioritized development strategy for evorpacept in combination with anti-cancer antibodies at R&D Day in March, Company is on track to initiate Phase 2 ASPEN-Breast and Phase 1 ASPEN-CRC studies in mid-2025 IND clearance received from U.S. FDA for novel EGFR-targeted antibody-drug conjugate (ADC), ALX2004, paving way for mid-year clinical program initiation; Company to host webcast focused on ALX2004 research program on May 20 Company will not pursue U.S. registrational path in gastric cancer following receipt of FDA feedback that accelerated approval pathway is not feasible based on ASPEN-06 due to standard-of-care evolving to ENHERTU® Data milestones expected across Company's three clinical programs in 2026 Cash runway has been extended into Q4 2026 SOUTH SAN FRANCISCO, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives, today reported financial results for the first quarter ended March 31, 2025, and provided a corporate update.» Mehr auf globenewswire.com
Historische Dividenden
Alle Dividenden KennzahlenUnternehmenszahlen
(EUR) | März 2025 | |
---|---|---|
Umsatz | 50,76 Mio | 10,77% |
Bruttoeinkommen | 27,13 Mio | 18,97% |
Nettoeinkommen | 11,38 Mio | 23,75% |
EBITDA | 30,04 Mio | 6,47% |
Fundamentaldaten
Metrik | Wert |
---|---|
Marktkapitalisierung | 1,01 Mrd€ |
Anzahl Aktien | 5,11 Mio |
52 Wochen-Hoch/Tief | 225,41€ - 165,51€ |
Dividendenrendite | 8,51% |
Dividenden TTM | 16,80€ |
Nächste Dividende | 4,03€ |
Beta | 0,74 |
KGV (PE Ratio) | 28,58 |
KGWV (PEG Ratio) | −3,27 |
KBV (PB Ratio) | 0,00 |
KUV (PS Ratio) | 5,13 |
Unternehmensprofil
Alexander's, Inc. ist ein Immobilien-Investment-Trust, der sieben Immobilien im Großraum New York City besitzt.
Name | ALEXANDER'S INC. DL 1 |
CEO | Steven Roth |
Sitz | Paramus, nj USA |
Website | |
Industrie | Diversifizierte REITs |
Börsengang | |
Mitarbeiter | 90 |
Ticker Symbole
Börse | Symbol |
---|---|
NYSE | ALX |
Frankfurt | AXE.F |
Düsseldorf | AXE.DU |
München | AXE.MU |
Assets entdecken
Shareholder von ALEXANDER'S INC. DL 1 investieren auch in folgende Assets